Aspects regarding nomenclature, classification and pathology of neuroendocrine neoplasms of the digestive system – a review

ION PĂUN1, GABRIEL BECHEANU2, ANDREI IONUȚ COSTIN3, VLAD DENIS CONSTANTIN4, GABRIELA-MARCELINA MIHAI5, LUCREȚIU RADU5, LARISA IOVAN3, FLORE VĂRCUȘ6

Abstract
Neuroendocrine neoplasms (NENs) of the digestive system are composed of cells with a neuroendocrine phenotype. These tumors produce and secrete peptide hormones and biogenic amines and they are called neuroendocrine neoplasms because of the marker proteins that they share with the neural cell system. The classification and nomenclature used to designate NENs have undergone changes over the past decades due to the accumulation of evidence related to the biological characteristics and their evolution. The European Neuroendocrine Tumor Society (ENETS) proposed a classification system based on the tumor grading and staging according to their localization. The latest internationally recognized NEN classification was published by the World Health Organization (WHO) in 2010. In accordance with the 2010 WHO criteria, the determination of the NEN malignancy potential is based on grading, depending on the mitotic activity and the Ki67 proliferation index, as well as on the tumor TNM stage. It is worth emphasizing that the terms neuroendocrine tumor (NET) and neuroendocrine carcinoma (NEC), without reference to grading or differentiation, are inadequate for prognostic assessment or the therapy determination, being inappropriate in pathology reports. The functional status of the tumor is based on the clinical findings but not on the pathological data or immunohistochemically profile. Despite the inability to establish a single system of sites, these are common features to establish the basis of most systems, documentation of these features allowing for greater reliability in the pathology reporting of these neoplasms.

Keywords: neuroendocrine neoplasms, pathology, classification, nomenclature, staging, grading.

Definitions
The term neuroendocrine tumor (NET) is used to describe a heterogeneous group of neoplasms formed by cells embodying two phenotypes: endocrine and neural.

The neuroendocrine phenotype is present in a series of cells that secrete amines and hormones under the name of diffuse endocrine system, a concept introduced by Feyrter in 1938 and later developed by Pearse in 1969, which features the amine precursor uptake and decarboxylation (APUD) diffuse system.

The diffuse neuroendocrine system associated with the gastroenteropancreatic tract consists of at least 14 types of cells showing autocrine, paracrine and local neuro-modulatory effects, which result from the differentiation of progenitor cells.

Normal neuroendocrine cells
There are three categories of neuroendocrine cells that can be morphologically identified by routine Hematoxylin–Eosin staining but only one type, namely enterochromaffin cells (ECs), can be recognized exclusively histologically, without the need for immunohistochemically tests or microscopic examination of cytoplasmic secretory granules.

Three cell types are described: ECs, open neuroendocrine cells and closed neuroendocrine cells [1].

Enterochromaffin cells
ECs are the most common neuroendocrine cells in the gastrointestinal tract and produce serotonin, a hormone responsible for the clinical manifestations of the carcinoid syndrome and P-subtype (produced by a subunit of ECs located in the jejunum and ileum). They constitute the majority of neuroendocrine cells in the small intestine mucosa (except the duodenum), appendix and colon, and may be seen as dispersed in the stomach and rectum. ECs are conical or polygonal in shape and small. The cytoplasm is directed towards the basement membrane, where it drains the secretion, is finely granular with eosinophilic granules. The round-oval nucleus is located to the crypt lumen and shows a fine chromatin, with no observable nucleoli.

“Open” neuroendocrine cells
“Open” neuroendocrine cells contain the cytoplasm that communicates with the crypt lumen. These are G-cells, D-cells (somatostatin secreting cells) and L-cells (enteroglucagon-secreting cells). G- and D-cells are found
for example, NETs are not related to cholecystokinin-
non-epithelial and do not have positive IHC expression
pancreas, bronchi and urogenital tract. The former are
on-site origin, such as neuroendocrine cells in the intestine,
cells, thyroid C-cells, parathyroid cells), and others have
dermal origin (paraganglion cells, olfactory cells, Merkel
considered to be outdated [3].

endocrine differentiation [1, 2].

of small-cell poor tumors. The identification of neuro-
purposes, but it may be used in the case of liver metastases
(IHC) expression of hormones does not necessarily
correlate with the presence of a functional tumor.

Electron microscopy is rarely required for diagnostic
purposes, but it may be used in the case of liver metastases of small-cell poor tumors. The identification of neuro-
secretory granules is a strong argument in favor of neuro-
endocrine differentiation [1, 2].

The system was formerly called APUD, a term currently
considered to be outdated [3].

Some of the neuroendocrine cells are of neuroecto-
dermal origin (paraganglion cells, olfactory cells, Merkel
cells, thyroid C-cells, parathyroid cells), and others have
on-site origin, such as neuroendocrine cells in the intestine,
pancreas, bronchi and urogenital tract. The former are
non-epithelial and do not have positive IHC expression
for cytokeratins.

Not all types of neuroendocrine cells give rise to NETs,
for example, NETs are not related to cholecystokininin-
and secretin-producing cells.

Neuroendocrine tumor

NET is a well differentiated neuroendocrine neoplasm (NEN), G1 or G2 according to the World Health Organization (WHO) classification of 2010, composed of cells similar to the normal intestinal endocrine ones and expressing general IHC markers of neuroendocrine differentiation (intense and diffuse positive expression of chromogranin A and synaptophysin) and hormone-specific tumor localization. Tumor endocrine cells display mild or moderate nuclear atypia and a small number of mitoses [<20 mitoses/10 high-power fields (HPFs)]. This entity includes neoplasms called carcinoids in the previous classifications [4].

Neuroendocrine carcinoma

The neuroendocrine carcinoma (NEC) is a poorly differentiated NEN composed of small tumor cells or large cells, which form NET-like organoid structures. The cells express diffusely neuroendocrine differentiation IHC markers (diffuse positive synaptophysin expression and weak expression of chromogranin A) and show marked nuclear atypia, multifocal necrosis and a large number of mitoses (>20 mitoses/10 HPFs) [5].

Mixed adenoneuroendocrine carcinoma

The mixed adenoneuroendocrine carcinoma (MANEC) is a malignant neoplasm in which two distinct morpho-
logical components can be identified, each present in a proportion higher than 30% of the tumor surface area. The presence of several immunohistochemically identifiable dissociated neuroendocrine cells is not sufficient for the tumor classification in this category. The presence of a squamous component is rare [5].

Neuroendocrine system cells, as well as tumors originating in them, share common antigens with nervous system elements, such as neuron-specific enolase (NSE), protein gene product 9.5 (PGP9.5), cluster of differentiation 56 (CD56), synaptophysin and chromosomes A, B and C. The expression of these common molecules is a strong
argument for using the term neuroendocrine neoplasm.

A number of scholars consider stem cells to be at the root of NENs, differentiating some primitive neuro-
endocrine precursor cells that can give rise to poorly differentiated NECs, or that can be further differentiated into programmed neuroendocrine precursor cells from which well differentiated NETs arise [6, 7].

In 1907, Oberndorfer noticed some small tumors in the small intestine, which he labeled Karzinoid, and for a long time the name of carcinoid tumors has been preserved for these types of neoplasms. The term carcinoid is still used by some authors as a synonym of well-
differentiated NETs [8].

Functional/nonfunctional neuroendocrine neoplasms

The hyperproduction of hormones at the level of NENs may result in the presence of a clinical syndrome,
in which case the NEN will be called functional NEN or NEN syndrome.

The carcinoid syndrome, present in 8–10% of NET-bearing patients, is generated by these tumors release of vasoactive substances, mainly serotonin, but also other such substances such as histamine and substance P, in the systemic circulation.

Due to serotonin inactivation largely in the liver, where it reaches through portal circulation, clinical manifes-
tations are obvious especially in the presence of liver metastases or in extradiges tive localizations (ovarian, bronchial, etc.).

The secretion of hormones by NENs is assessed immunohistochemically, nevertheless, the classification is not exclusively based on immunophenotypes, but in correlation with the functional status of the tumor. Thus, a tumor will be named after the hormone produced, using predominantly the suffix “-oma” (e.g., insulinoma) only if there is a clinical syndrome determined by it [9].

In the absence of clinical manifestations, in the histo-
pathological report the term “neuroendocrine tumor of ...” is accepted, depending on the immunophenotype of the neoplasm.

Frequently, small-cell populations that produce other peptides with hormonal effects are identified in the tumor.
It is possible that NEN metastases may express other hormones than the primary tumor [10].

Classification and nomenclature of neuroendocrine neoplasms of the digestive system

The classification and nomenclature used to designate NENs have undergone changes over the past decades due to the collection of evidence related to biological characteristics and their evolution [8, 11–13].

The latest internationally recognized classification was published by the WHO in 2010 [14] (Table 1).

Table 1 – WHO 2000 compared to WHO 2010 classification of tumors of the digestive system (from Bosman et al., 2010) [11]

<table>
<thead>
<tr>
<th>WHO 2000</th>
<th>WHO 2010</th>
</tr>
</thead>
<tbody>
<tr>
<td>Well-differentiated endocrine tumor</td>
<td>NET G1 (carcinoid)</td>
</tr>
<tr>
<td>Well-differentiated endocrine carcinoma</td>
<td>NET G2</td>
</tr>
<tr>
<td>Low differentiated endocrine carcinoma/small-cell carcinoma</td>
<td>NEC (large-cell or small-cell) G3</td>
</tr>
<tr>
<td>Mixed exocrine-endocrine carcinoma</td>
<td>Mixed adenoneuroendocrine carcinoma</td>
</tr>
<tr>
<td>Tumor-like lesions</td>
<td>Hyperplasic and preneoplastic lesions</td>
</tr>
</tbody>
</table>


Prior to this, the European Society for Neuroendocrine Tumors (ENETS) proposed two complementary tools to classify them: a classification according to the tumor grading and staging according to localization [15, 16].

ENETS highlighted a number of key concepts related to the way NENs are considered today:

- NEN heterogeneity (different primitive localizations);
- Tumor differentiation;
- Malignancy (long-term monitoring indicates that the NEN, as a family of tumors, is malignant).

For NEN grading, morphological criteria (specific to NEN localization) and proliferation fraction assessment (according to ENETS) are used (Table 2).

Table 2 – Grading for digestive NETs (from Couvelard, 2015) [11]

<table>
<thead>
<tr>
<th>Grade of differentiation</th>
<th>Criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>G1</td>
<td>&lt;2 mitoses/10 HPFs and/or ≤2% Ki67 index</td>
</tr>
<tr>
<td>G2</td>
<td>2–20 mitoses/10 HPFs and/or 3–20% Ki67 index</td>
</tr>
<tr>
<td>G3</td>
<td>&gt;20 mitoses/10 HPFs and/or &gt;20% Ki67 index</td>
</tr>
</tbody>
</table>

NET: Neuroendocrine tumors; HPFs: High power fields.

In this grading system it is necessary to perform a mitotic count in at least 50 HPFs (2 mm²), and to estimate the proliferation index, and the percentage of positive cells out of the 500–2000 cells evaluated in the hot spot area has to be used. If the mitotic count and the proliferation index indicate different grades, the lesser grade of differentiation will be taken into consideration [5, 17].

Well and intermediate differentiated tumors (G1 and G2) may show malignant potential by local invasion and/or lymph nodes or distant metastases (Table 3).

Table 3 – Pathology reporting of NETs: essential elements for accurate diagnosis, classification, and staging (from Klimstra, 2013) [17]

<table>
<thead>
<tr>
<th>NEN</th>
<th>NET</th>
<th>NEC</th>
</tr>
</thead>
<tbody>
<tr>
<td>Grade of differentiation</td>
<td>Well differentiated (G1, G2)</td>
<td>Poorly differentiated (G3)</td>
</tr>
<tr>
<td>Hormonal expression (specific local hormones)</td>
<td>Present</td>
<td>Absent</td>
</tr>
<tr>
<td>Hormonal syndromes (functional tumors)</td>
<td>Present</td>
<td>Absent</td>
</tr>
<tr>
<td>Genetic</td>
<td>Miscellaneous</td>
<td>p53 and RB genes mutations</td>
</tr>
</tbody>
</table>

NEN: Neuroendocrine neoplasm; NET: Neuroendocrine tumor; NEC: Neuroendocrine carcinoma; RB: Retinoblastoma.

Cyto-morphological modifications of aggressive behavior (cellular atypia, higher mitotic index, vascular invasion) do not determine the classification of a tumor as a malignancy, but as a “well differentiated tumor with uncertain behavior” in the absence of local or remote dissemination [17, 18].

In accordance with the WHO 2010 criteria, the determination of malignant potential groups is based on both grading, mitotic and Ki67 activity, and TNM tumor status [5, 17].

To improve prognostic relevance, ENETS recommends the use of the grading system in conjunction with a staging system specific to each gastroenteropancreatic localization [17, 19].

Unlike previous classifications, this identification of the tumor stage also applies to NEN metastases. Both grading and TMN staging specific to localization are required to define the malignant potential [18, 19].

A staging system for digestive tract NEN has been proposed through modifying or accepting TMN stages corresponding to carcinomas with the same localization [17, 19].

There are some significant differences between the European NEN staging system adopted in 2006 (ENETS) and the one adopted by the American Joint Committee on Cancer (AJCC) in 2009 for the stomach and appendix and the absence of a specific incidence of mixed carcinomas, depending on the exocrine or endocrine component [19].

Staging is based primarily on criteria such as: tumor size, invasion of the muscularis mucosae, serosa and adjacent structures [18–20].

Histological patterns of neuroendocrine neoplasms

Type A (island or nest)

This histological pattern is particularly characteristic of NETs with ECs. The tumor is composed of nests, islands or stretches in which cells are organized compactly, evenly, are monomorphic and show no mitotic activity. There is only a minimal fibro-vascular tissue between the cellular cords. Sometimes, there is a vague dissection in the peripheral palisades of neuroendocrine cell nuclei. The histological type A indicates a primitive localization of a NET in the digestive tract of embryonic origin in the middle intestine (duodenum II, III and IV, jejunum, ileum,
following essential minimum data:

Type B (trabecula)

Type B prevails in L-cells, most commonly encountered in the rectum. Tumor cells form trabecular or long rods, usually a cell thick, which may be curvilinear, similar to garlands, or short, like an infiltrative mammary lobular carcinoma. The stroma is very small, there are no atypia or mitoses, and necrosis is absent or minimal. The presence of the pure B-type is specific to the NET with gastrointestinal localization deriving from the caudal intestine (the distal third of the transverse colon, descending colon, sigmoid and rectum).

Type C (acinar)

NET cells of the histological type C form adenoidal lumen structures that sometimes contain secretions and bodies of psammoma, with no identification of true glands. The cells are polygonal, small, and the nuclei are not directed towards the basement membrane. The acinar type is commonly found in somatostatin-producing duodenal NETs. However, the exclusive presence of type C does not apply to all gastrointestinal sites derived from the anterior intestine, and a combination of histological patterns is customarily noticed in the stomach.

Type D (poorly differentiated)

In this histological type, tumor cells exhibit neuroendocrine nuclear features but with a high nuclear/cytoplasm ratio and a disorganized, trabecular pattern and in poorly defined nests. This histopathological aspect indicates malignant behavior, and it can be observed focally in colonic NETs, alongside types A and B of neuroendocrine patterns [1, 2].

Essential minimum data in the histopathology report recommended by the WHO

For the histopathology report, WHO recommended the following essential minimum data [13, 16]:

**Macroscopic data:**
- Exact localization of the tumor;
- Exact size of the tumor;
- Distance to the edge of the resection.

**Microscopic data:**
- Mitotic count per 10 HPFs;
- Number of evaluated fields;
- Ki67 proliferation index.

**Mandatory elements for the final diagnosis:**
- Tumor classification (TNM or CNE);
- Tumor grade (G1, G2 or G3);
- TNM staging specific to localization (for tumor resection).

**Optional histopathological data:**
- Immunohistochemically detectable endocrine profile (does not necessarily correlate with the presence of a clinical syndrome of excessive hormone production by the tumor).

Immunohistochemistry of neuroendocrine neoplasms

Neuroendocrine cells can be identified immunohistochemically by membrane or cytoplasmic markers. Somatostatin receptors (SSTRs) and CD56 show a membrane reaction. NSE and PGP9.5 may be positive for cytoplasm. The cytoplasm of neuroendocrine cells may contain two types of secretory vesicles: synaptic-like small vesicles evidenced by synaptophysin, and larger vesicles with a positive IHC reaction to chromogranin A and other markers such as vesicular monoamine transporter (VMAT).

The positive expression of common markers with cells of nerve origin (synaptophysin, CD56, PGP9.5 and NSE) is an argument for using the term neuroendocrine neoplasm [21–23].

For the accurate determination of neuroendocrine differentiation it is recommended to use a panel of at least two antibodies that include synaptophysin and chromogranin A, considered to be general neuroendocrine markers [24].

NETs (G1, G2) are usually diffuse and strongly positive in the two markers, whereas NECs (G3) usually express diffuse synaptophysin and express poorly, focally or negatively for chromogranin A [22, 23].

The production of hormones by the tumor can be studied immunohistochemically, but tissue expression does not necessarily correlate with the presence of a clinical syndrome determined by hormonal overproduction, and thus of a functional tumor. Admittedly, the name of a tumor based solely on the hormone immunophenotype using the suffix “-oma” (insulinoma, glucagon) is not correct.

Typically, NETs predominantly contain a type of hormone (e.g., gastrin in gastrinomas, somatostatin in somatostatinomas, etc.) that can cause clinical manifestations, but there are usually minor cell populations expressing other hormones, such as cholecystokinin, secretin, pancreatic polypeptide (PP), adrenocorticotropic hormone (ACTH), substance P, neurotensin, motilin [25, 26].

The metastasis of NENs may have a hormonal immunophenotype different from the primary tumor. Most NETs with gastrointestinal localization of embryonic origin in the mid-intestine (distal, ileum, colon, jejunum) are positive for caudal-type homeobox 2 (CDX2), while most rectal NETs are negative. NECs may have nuclear IHC reaction for p53 [27–29].

**Proliferation index**

To assess the grade of tumor differentiation, it is necessary to evaluate the mitotic count and/or the Ki67 proliferation index according to the ENETS scheme. While the mitotic count is difficult to standardize, the nuclear expression of Ki67 is more objective. Thus, tumors displaying Ki67 ≤2% proliferation index and/or mitotic count ≤2 mitoses/10 HPFs correspond to G1 grade, those with a Ki67 index ranging between 3% and 20% and/or 2–20 mitoses/10 HPFs correspond to G2 grade and Ki67 index >20% and/or mitotic count >20 mitoses/10 HPFs correspond to G3 grade.
This classification according to the tumor grade has a prognostic value and correlates with the tumor size and its metastasis capacity [3, 30].

**Determination of primitive origin of NEN metastases**

NENs most commonly metastasize to the liver, lungs and bones. Rare localizations of NEN metastases are cerebral, cardiac, ovarian, mammary, thyroid, pancreatic, splenic, renal, dermal, suprarenal, orbital and pituitary.

The IHC markers thyroid transcription factor 1 (TTF1) and CDX2 are very useful to assess the primary origin of a NEN. TTF1 is positive in over 90% of typical and atypical pulmonary carcinoids as well as in large-cell pulmonary NECs, and it is rarely expressed in NETs with extra-pulmonary primitive localization [31, 32].

In contrast, extra-pulmonary small-cell carcinomas are positive for TTF1 (in 40–80% of cases), making the differential diagnosis difficult [33].

CDX2 is a marker specific to digestive differentiation, many of the gastrointestinal NENs being positive, especially those with primitive hernia, ileal and colonic localization [33, 34].

Pancreatic NENs show pancreatic and duodenal homeobox 1 (PDX1), insulin gene enhancer protein (ISL1) positivity, as well as for neuroendocrine secretory protein 55 (NESP55), a member of the chromogranin family [35].

CDX2, carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA19-9) may also be positive in NETs of pancreatic origin [36].

**Molecular pathology**

Unlike adenocarcinomas, NEN pathogenesis has not demonstrated systematic progression through successive mutations towards malignancy. Instead, NENs exhibit specific biological behavior depending on their localization and embryological origin.

NENs of the digestive tract derived from the former primitive intestine frequently present chromosome 11q13 changes in the menin 1 (MEN1) gene locus encoding the protein called menin [37].

Anomalies of this gene are responsible for the occurrence of MEN1 syndrome, where there is a combination of multiple endocrine tumors in the pituitary gland, parathyroid gland, pancreas, and stomach [38].

Other genetic modifications are described as loss of heterozygosity (LOH) 11q13, overexpression of Erb-b2 receptor tyrosine kinase 2 (ERBB2) on chromosome 17q21, loss of B-cell lymphoma 2 (BCL2) expression (in type 1 gastric NET) and others [37, 38].

NENs of the intestinal tract derived from the primitive mid-intestine present anomalies of the chromosome 18q, and losses of 11q, 16q. LOH at chromosome 18 was identified in 86% of ileum NETs. Other genes involved in the NEN pathogenesis of the mid-intestinal tract are deleted in colorectal carcinoma (DCC), deleted in pancreatic carcinoma locus 4 (DPYC/SMAD4), cadherin 1 (CDH1), CTCF and MYC (c-myc) [39, 40].

NENs with intestine localization derived from the caudal intestinal tract present totally different genetic changes.

Epidermal growth factor receptor (EGFR), a member of the human epidermal growth factor receptor 2 (HER2) transmembrane signaling protein family, is overexpressed in NEN and in the presence of metastases [41].

An abnormal expression of transforming growth factor-beta (TGF-β) has also been observed. Another frequent change is represented by gene silencing through methylation. Also, β-catenin is overexpressed in 79% of the digestive NENs with this localization [41].

In addition to the multiple endocrine neoplasia (MEN) syndrome, other genetic syndromes associated with NENs are neurofibromatosis type 1 (NF1) (ampullary and periampullary NET), von Hippel–Lindau (VHL) disease (functional duodenal NET producing somatostatin and pancreatic NET), and Bourneville tuberous sclerosis [41].

**Conflict of interests**

The authors declare that there is no conflict of interests regarding the publication of this paper.

**References**


